Austrian biotech company CEBINA GmbH on Wednesday reported positive results from its COVID-19 drug repurposing project with the identification of commonly used approved drugs with activity against SARS-CoV-2 infection in in vitro assays.
The results show that five generic drugs demonstrate anti-SARS-CoV-2 activity.
One of these drugs, antihistamine nasal spray Azelastine, has been identified as a potential topical preventive or post-exposure anti-COVID-19 approach. The other identified drugs are commonly used in anti-hypertensive therapy: Telmisartan, Metoprolol, Losartan and Amiloride.
CEBINA said that it has applied for patent protection for its findings and will publish the scientific data shortly. The company is also in discussion with pharma manufacturer Sigmapharm Arzneimittel GmbH for the development and production of an Azelastine product.
To accelerate access to this anti-COVID-19 approach with broad availability adequate for the global need, CEBINA is open to third party financing and will be seeking licensing partners for worldwide distribution.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling